Ritodrinium [Inn-Latin] en es it fr

Ritodrinium [Inn-Latin] Brand names, Ritodrinium [Inn-Latin] Analogs

Ritodrinium [Inn-Latin] Brand Names Mixture

  • No information avaliable

Ritodrinium [Inn-Latin] Chemical_Formula


Ritodrinium [Inn-Latin] RX_link

No information avaliable

Ritodrinium [Inn-Latin] fda sheet

Ritodrinium [Inn-Latin] msds (material safety sheet)

Ritodrinium_[Inn-Latin] MSDS

Ritodrinium [Inn-Latin] Synthesis Reference

Belg. pat. 660.244 (1965 to N.V. Philips), C.A. 63, 17965h (1965) corresp to Claassen et al., U.S. pat. 3,410,944 (1968 to No. Am. Philips)

Ritodrinium [Inn-Latin] Molecular Weight

287.354 g/mol

Ritodrinium [Inn-Latin] Melting Point

88-90 oC

Ritodrinium [Inn-Latin] H2O Solubility


Ritodrinium [Inn-Latin] State


Ritodrinium [Inn-Latin] LogP


Ritodrinium [Inn-Latin] Dosage Forms

Solution for IV; Capsule (extended-release); Tablet; Intramuscular injection

Ritodrinium [Inn-Latin] Indication

For the treatment and prophylaxis of premature labour

Ritodrinium [Inn-Latin] Pharmacology

Beta-2 adrenergic receptors are located at sympathetic neuroeffector junctions of many organs, including uterus. Ritodrine is beta-2 adrenergic agonist. It stimulates beta-2 adrenergic receptor, increases cAMP level and decreases intracellular calcium concentration. The decrease of calcium concentration leads to a relaxation of uterine smooth muscle.

Ritodrinium [Inn-Latin] Absorption

No information avaliable

Ritodrinium [Inn-Latin] side effects and Toxicity

LD50=64mg/kg (mice, IV); LD50=540 mg/kg (mice, oral); LD50=85 mg/kg (rat, IV)

Ritodrinium [Inn-Latin] Patient Information

Ritodrinium [Inn-Latin] Organisms Affected

Humans and other mammals